216 related articles for article (PubMed ID: 26232370)
21. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
Otsuka K; Hata A; Takeshita J; Okuda C; Kaji R; Masago K; Fujita S; Katakami N
Cancer Chemother Pharmacol; 2015 Oct; 76(4):835-41. PubMed ID: 26349474
[TBL] [Abstract][Full Text] [Related]
22. Erlotinib Plus Bevacizumab Phase ll Study in Patients with Advanced Non-small-Cell Lung Cancer (JO25567): Updated Safety Results.
Kato T; Seto T; Nishio M; Goto K; Yamamoto N; Okamoto I; Tao L; Yu W; Khaznadar T; Tajima K; Shibata M; Seki A; Yamamoto N
Drug Saf; 2018 Feb; 41(2):229-237. PubMed ID: 29043496
[TBL] [Abstract][Full Text] [Related]
23. MO06.03 Bevacizumab and erlotinib or bevacizumab, cisplatin and pemetrexed in patients with metastatic non-small cell lung cancer: EGFR mutation based treatment allocation and repeat biopsy at progression in the SAKK19/09 (BIOPRO) trial.
Clin Adv Hematol Oncol; 2014 Jan; 12(1 Suppl 1):13. PubMed ID: 24852397
[No Abstract] [Full Text] [Related]
24. ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer.
Johnson BE; Kabbinavar F; Fehrenbacher L; Hainsworth J; Kasubhai S; Kressel B; Lin CY; Marsland T; Patel T; Polikoff J; Rubin M; White L; Yang JC; Bowden C; Miller V
J Clin Oncol; 2013 Nov; 31(31):3926-34. PubMed ID: 24101054
[TBL] [Abstract][Full Text] [Related]
25. New therapy targets resistant non-small-cell lung cancers.
Jenks S
J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25421346
[No Abstract] [Full Text] [Related]
26. Ongoing trials with bevacizumab and other antiangiogenic agents in lung cancer.
Dowlati A
Clin Lung Cancer; 2008 Mar; 9 Suppl 2():S71-5. PubMed ID: 21885002
[TBL] [Abstract][Full Text] [Related]
27. [III. Role of Anti-Angiogenesis Therapy for Advanced Non-Small Cell Lung Cancer - Current Status and Future Challenges].
Hirai F
Gan To Kagaku Ryoho; 2015 Aug; 42(8):940-3. PubMed ID: 26353391
[No Abstract] [Full Text] [Related]
28. 24h-gene variation effect of combined bevacizumab/erlotinib in advanced non-squamous non-small cell lung cancer using exon array blood profiling.
Baty F; Joerger M; Früh M; Klingbiel D; Zappa F; Brutsche M
J Transl Med; 2017 Mar; 15(1):66. PubMed ID: 28359318
[TBL] [Abstract][Full Text] [Related]
29. In focus: non-small cell lung cancer: E1505.
Clin Adv Hematol Oncol; 2007 Mar; 5(3):206-8. PubMed ID: 17519882
[No Abstract] [Full Text] [Related]
30. New options for integrating antiangiogenic therapy and platinum-based first-line chemotherapy for advanced non-small-cell lung cancer.
Manegold C
Clin Lung Cancer; 2008; 9 Suppl 3():S100-8. PubMed ID: 19419923
[TBL] [Abstract][Full Text] [Related]
31. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.
Seto T; Kato T; Nishio M; Goto K; Atagi S; Hosomi Y; Yamamoto N; Hida T; Maemondo M; Nakagawa K; Nagase S; Okamoto I; Yamanaka T; Tajima K; Harada R; Fukuoka M; Yamamoto N
Lancet Oncol; 2014 Oct; 15(11):1236-44. PubMed ID: 25175099
[TBL] [Abstract][Full Text] [Related]
32. New antiangiogenetic agents and non-small cell lung cancer.
Gridelli C; Rossi A; Maione P
Crit Rev Oncol Hematol; 2006 Oct; 60(1):76-86. PubMed ID: 16843002
[TBL] [Abstract][Full Text] [Related]
33. How should we use bevacizumab in patients with non-small cell lung cancer?
Kim YH; Mishima M
J Thorac Oncol; 2011 Dec; 6(12):2145-6. PubMed ID: 22088996
[No Abstract] [Full Text] [Related]
34. [Lung cancer: an update in 2010].
Besse B; Vignot S; Soria JC
Bull Cancer; 2010 Jan; 97(1):161-9. PubMed ID: 20028651
[TBL] [Abstract][Full Text] [Related]
35. A novel synergistic effect of iron depletion on antiangiogenic cancer therapy.
Ohara T; Noma K; Urano S; Watanabe S; Nishitani S; Tomono Y; Kimura F; Kagawa S; Shirakawa Y; Fujiwara T
Int J Cancer; 2013 Jun; 132(11):2705-13. PubMed ID: 23161652
[TBL] [Abstract][Full Text] [Related]
36. The use of bevacizumab in non-small cell lung cancer: an update.
Lauro S; Onesti CE; Righini R; Marchetti P
Anticancer Res; 2014 Apr; 34(4):1537-45. PubMed ID: 24692680
[TBL] [Abstract][Full Text] [Related]
37. Bevacizumab and erlotinib: a promising new approach to the treatment of advanced NSCLC.
Herbst RS; Sandler A
Oncologist; 2008 Nov; 13(11):1166-76. PubMed ID: 18997180
[TBL] [Abstract][Full Text] [Related]
38. Perfusion CT allows prediction of therapy response in non-small cell lung cancer treated with conventional and anti-angiogenic chemotherapy.
Tacelli N; Santangelo T; Scherpereel A; Duhamel A; Deken V; Klotz E; Cortot A; Lafitte JJ; Wallyn F; Remy J; Remy-Jardin M
Eur Radiol; 2013 Aug; 23(8):2127-36. PubMed ID: 23553586
[TBL] [Abstract][Full Text] [Related]
39. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer.
Herbst RS; Johnson DH; Mininberg E; Carbone DP; Henderson T; Kim ES; Blumenschein G; Lee JJ; Liu DD; Truong MT; Hong WK; Tran H; Tsao A; Xie D; Ramies DA; Mass R; Seshagiri S; Eberhard DA; Kelley SK; Sandler A
J Clin Oncol; 2005 Apr; 23(11):2544-55. PubMed ID: 15753462
[TBL] [Abstract][Full Text] [Related]
40. [From ASCO and WCLC 2005 to the clinical practice: targeted therapies].
Pérol M
Rev Pneumol Clin; 2006 Feb; 62 Spec no 1():1S30-4. PubMed ID: 16719154
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
